Comprehensive Analysis Reveals USP45 as a Novel Putative Oncogene in Pan-Cancer

Background: Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of target proteins and playing an important role in tumor. However, the mechanism of deubiquitinating enzyme USP45 in tumors remains unclear. Method...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in molecular biosciences Vol. 9; p. 886904
Main Authors Li, Kai, Wang, Qian, Bian, Hua, Chen, Zhiguo, He, Haifa, Zhao, Xulin, Gong, Pengju
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 28.06.2022
Subjects
Online AccessGet full text
ISSN2296-889X
2296-889X
DOI10.3389/fmolb.2022.886904

Cover

Loading…
Abstract Background: Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of target proteins and playing an important role in tumor. However, the mechanism of deubiquitinating enzyme USP45 in tumors remains unclear. Methods: Based on the RNA-seq data of tissues and cell lines in The Cancer Genome Atlas (TCGA) database, GTEx and CCLE database, the pan-cancer analysis of USP45 expression and survival outcome were performed using R software and Kaplan-Meier Plotter. The structural variants, gene mutations and gene copy number alteration of USP45 were analyzed using the TCGA Pan-Cancer Atlas Studies dataset in the cBioPortal database. The relationships between USP45 and mRNA methylation, tumor heterogeneity, tumor stemness, and tumor immunity were performed by Sangerbox platform and TIMER2.0 using Pearson correlation analysis. Through the ENCORI database and string database, we constructed the ceRNA regulatory mechanism and protein-protein interaction network for USP45. Based on the RNA-seq data in TCGA and GTEx databases, we also constructed the downstream regulatory network for USP45 using the Limma and ClusterProfiler packages of R software. At last, the protein expression levels of USP45 were detected by immunohistochemistry in tumor tissue microarrays. Results: USP45 is upregulated in most types of tumors and negatively correlated with the overall survival and recurrence-free survival of patient. Furthermore, the structural variation, gene mutations and gene copy number variation of USP45 were identified in different types of tumors. The pan-cancer analysis showed that USP45 was closely related to mRNA methylation, tumor heterogeneity and tumor stemness. In most types of tumors, the expression of USP45 was positively correlated with many immune checkpoint molecules and immune regulators such as PD-L1, while negatively correlated with the infiltration levels of NK cells, Th1 cells, macrophages, and dendritic cells in the tumor microenvironment. Finally, we constructed the ceRNA regulatory network, protein-protein interaction network and downstream regulatory network for USP45 in different types of tumors. Conclusion: Our study firstly explored the putative oncogenic role of USP45 in pan-cancer, and provided insights for further investigation of USP45.
AbstractList Background: Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of target proteins and playing an important role in tumor. However, the mechanism of deubiquitinating enzyme USP45 in tumors remains unclear.Methods: Based on the RNA-seq data of tissues and cell lines in The Cancer Genome Atlas (TCGA) database, GTEx and CCLE database, the pan-cancer analysis of USP45 expression and survival outcome were performed using R software and Kaplan-Meier Plotter. The structural variants, gene mutations and gene copy number alteration of USP45 were analyzed using the TCGA Pan-Cancer Atlas Studies dataset in the cBioPortal database. The relationships between USP45 and mRNA methylation, tumor heterogeneity, tumor stemness, and tumor immunity were performed by Sangerbox platform and TIMER2.0 using Pearson correlation analysis. Through the ENCORI database and string database, we constructed the ceRNA regulatory mechanism and protein-protein interaction network for USP45. Based on the RNA-seq data in TCGA and GTEx databases, we also constructed the downstream regulatory network for USP45 using the Limma and ClusterProfiler packages of R software. At last, the protein expression levels of USP45 were detected by immunohistochemistry in tumor tissue microarrays.Results: USP45 is upregulated in most types of tumors and negatively correlated with the overall survival and recurrence-free survival of patient. Furthermore, the structural variation, gene mutations and gene copy number variation of USP45 were identified in different types of tumors. The pan-cancer analysis showed that USP45 was closely related to mRNA methylation, tumor heterogeneity and tumor stemness. In most types of tumors, the expression of USP45 was positively correlated with many immune checkpoint molecules and immune regulators such as PD-L1, while negatively correlated with the infiltration levels of NK cells, Th1 cells, macrophages, and dendritic cells in the tumor microenvironment. Finally, we constructed the ceRNA regulatory network, protein-protein interaction network and downstream regulatory network for USP45 in different types of tumors.Conclusion: Our study firstly explored the putative oncogenic role of USP45 in pan-cancer, and provided insights for further investigation of USP45.
Background: Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of target proteins and playing an important role in tumor. However, the mechanism of deubiquitinating enzyme USP45 in tumors remains unclear. Methods: Based on the RNA-seq data of tissues and cell lines in The Cancer Genome Atlas (TCGA) database, GTEx and CCLE database, the pan-cancer analysis of USP45 expression and survival outcome were performed using R software and Kaplan-Meier Plotter. The structural variants, gene mutations and gene copy number alteration of USP45 were analyzed using the TCGA Pan-Cancer Atlas Studies dataset in the cBioPortal database. The relationships between USP45 and mRNA methylation, tumor heterogeneity, tumor stemness, and tumor immunity were performed by Sangerbox platform and TIMER2.0 using Pearson correlation analysis. Through the ENCORI database and string database, we constructed the ceRNA regulatory mechanism and protein-protein interaction network for USP45. Based on the RNA-seq data in TCGA and GTEx databases, we also constructed the downstream regulatory network for USP45 using the Limma and ClusterProfiler packages of R software. At last, the protein expression levels of USP45 were detected by immunohistochemistry in tumor tissue microarrays. Results: USP45 is upregulated in most types of tumors and negatively correlated with the overall survival and recurrence-free survival of patient. Furthermore, the structural variation, gene mutations and gene copy number variation of USP45 were identified in different types of tumors. The pan-cancer analysis showed that USP45 was closely related to mRNA methylation, tumor heterogeneity and tumor stemness. In most types of tumors, the expression of USP45 was positively correlated with many immune checkpoint molecules and immune regulators such as PD-L1, while negatively correlated with the infiltration levels of NK cells, Th1 cells, macrophages, and dendritic cells in the tumor microenvironment. Finally, we constructed the ceRNA regulatory network, protein-protein interaction network and downstream regulatory network for USP45 in different types of tumors. Conclusion: Our study firstly explored the putative oncogenic role of USP45 in pan-cancer, and provided insights for further investigation of USP45.
Background: Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of target proteins and playing an important role in tumor. However, the mechanism of deubiquitinating enzyme USP45 in tumors remains unclear. Methods: Based on the RNA-seq data of tissues and cell lines in The Cancer Genome Atlas (TCGA) database, GTEx and CCLE database, the pan-cancer analysis of USP45 expression and survival outcome were performed using R software and Kaplan-Meier Plotter. The structural variants, gene mutations and gene copy number alteration of USP45 were analyzed using the TCGA Pan-Cancer Atlas Studies dataset in the cBioPortal database. The relationships between USP45 and mRNA methylation, tumor heterogeneity, tumor stemness, and tumor immunity were performed by Sangerbox platform and TIMER2.0 using Pearson correlation analysis. Through the ENCORI database and string database, we constructed the ceRNA regulatory mechanism and protein-protein interaction network for USP45. Based on the RNA-seq data in TCGA and GTEx databases, we also constructed the downstream regulatory network for USP45 using the Limma and ClusterProfiler packages of R software. At last, the protein expression levels of USP45 were detected by immunohistochemistry in tumor tissue microarrays. Results: USP45 is upregulated in most types of tumors and negatively correlated with the overall survival and recurrence-free survival of patient. Furthermore, the structural variation, gene mutations and gene copy number variation of USP45 were identified in different types of tumors. The pan-cancer analysis showed that USP45 was closely related to mRNA methylation, tumor heterogeneity and tumor stemness. In most types of tumors, the expression of USP45 was positively correlated with many immune checkpoint molecules and immune regulators such as PD-L1, while negatively correlated with the infiltration levels of NK cells, Th1 cells, macrophages, and dendritic cells in the tumor microenvironment. Finally, we constructed the ceRNA regulatory network, protein-protein interaction network and downstream regulatory network for USP45 in different types of tumors. Conclusion: Our study firstly explored the putative oncogenic role of USP45 in pan-cancer, and provided insights for further investigation of USP45.Background: Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of target proteins and playing an important role in tumor. However, the mechanism of deubiquitinating enzyme USP45 in tumors remains unclear. Methods: Based on the RNA-seq data of tissues and cell lines in The Cancer Genome Atlas (TCGA) database, GTEx and CCLE database, the pan-cancer analysis of USP45 expression and survival outcome were performed using R software and Kaplan-Meier Plotter. The structural variants, gene mutations and gene copy number alteration of USP45 were analyzed using the TCGA Pan-Cancer Atlas Studies dataset in the cBioPortal database. The relationships between USP45 and mRNA methylation, tumor heterogeneity, tumor stemness, and tumor immunity were performed by Sangerbox platform and TIMER2.0 using Pearson correlation analysis. Through the ENCORI database and string database, we constructed the ceRNA regulatory mechanism and protein-protein interaction network for USP45. Based on the RNA-seq data in TCGA and GTEx databases, we also constructed the downstream regulatory network for USP45 using the Limma and ClusterProfiler packages of R software. At last, the protein expression levels of USP45 were detected by immunohistochemistry in tumor tissue microarrays. Results: USP45 is upregulated in most types of tumors and negatively correlated with the overall survival and recurrence-free survival of patient. Furthermore, the structural variation, gene mutations and gene copy number variation of USP45 were identified in different types of tumors. The pan-cancer analysis showed that USP45 was closely related to mRNA methylation, tumor heterogeneity and tumor stemness. In most types of tumors, the expression of USP45 was positively correlated with many immune checkpoint molecules and immune regulators such as PD-L1, while negatively correlated with the infiltration levels of NK cells, Th1 cells, macrophages, and dendritic cells in the tumor microenvironment. Finally, we constructed the ceRNA regulatory network, protein-protein interaction network and downstream regulatory network for USP45 in different types of tumors. Conclusion: Our study firstly explored the putative oncogenic role of USP45 in pan-cancer, and provided insights for further investigation of USP45.
Author Li, Kai
Bian, Hua
Wang, Qian
Gong, Pengju
Chen, Zhiguo
He, Haifa
Zhao, Xulin
AuthorAffiliation 1 Zhang Zhongjing College of Chinese Medicine , Nanyang Institute of Technology , Nanyang , China
2 Henan Key Laboratory of Zhang Zhongjing Formulae and Herbs for Immunoregulation , Nanyang Institute of Technology , Nanyang , China
3 School of Basic Medical Sciences , Xinxiang Medical University , Xinxiang , China
4 Department of Pathology , Central Hospital of Nanyang City , Nanyang , China
6 The University of Texas MD Anderson Cancer Center UThealth Graduate School of Biomedical Sciences , Houston , TX , United States
5 Department of Oncology , The First People’s Hospital of Nanyang , Nanyang , China
AuthorAffiliation_xml – name: 3 School of Basic Medical Sciences , Xinxiang Medical University , Xinxiang , China
– name: 5 Department of Oncology , The First People’s Hospital of Nanyang , Nanyang , China
– name: 1 Zhang Zhongjing College of Chinese Medicine , Nanyang Institute of Technology , Nanyang , China
– name: 6 The University of Texas MD Anderson Cancer Center UThealth Graduate School of Biomedical Sciences , Houston , TX , United States
– name: 2 Henan Key Laboratory of Zhang Zhongjing Formulae and Herbs for Immunoregulation , Nanyang Institute of Technology , Nanyang , China
– name: 4 Department of Pathology , Central Hospital of Nanyang City , Nanyang , China
Author_xml – sequence: 1
  givenname: Kai
  surname: Li
  fullname: Li, Kai
– sequence: 2
  givenname: Qian
  surname: Wang
  fullname: Wang, Qian
– sequence: 3
  givenname: Hua
  surname: Bian
  fullname: Bian, Hua
– sequence: 4
  givenname: Zhiguo
  surname: Chen
  fullname: Chen, Zhiguo
– sequence: 5
  givenname: Haifa
  surname: He
  fullname: He, Haifa
– sequence: 6
  givenname: Xulin
  surname: Zhao
  fullname: Zhao, Xulin
– sequence: 7
  givenname: Pengju
  surname: Gong
  fullname: Gong, Pengju
BookMark eNp9kUtr3DAURkVJaB7ND-jOy248kfWwpE0hDH0EQmfIA7oT1_L1RMGWppJnIP--diaUpouurrj6viPBOSNHIQYk5GNFF5xrc9kNsW8WjDK20Lo2VLwjp4yZutTa_Dz663xCLnJ-opRWknJVi_fkhEvNa8P5KVkt47BN-Igh-z0WVwH65-xzcYt7hD4XD3drIQvIBRQ_4h77Yr0bYZyjq-DiBgMWPhRrCOUSgsP0gRx3Uw8vXuc5efj65X75vbxZfbteXt2UTgg2lkyqjhunG82ZBKUldK6mVErVTtNoDpWSrWaO605LLbSWCiSjbVU306bl5-T6wG0jPNlt8gOkZxvB25dFTBsLafSuR0uxE8K1rpuIQgMDjpU0rWoUUGqAT6zPB9Z21wzYOgxjgv4N9O1N8I92E_fWMMVNxSbAp1dAir92mEc7-Oyw7yFg3GXLalNRoTSjU7Q6RF2KOSfs_jxTUTt7tS9e7ezVHrxOHfVPx_lZQpx_4_v_NH8D9A2o6Q
CitedBy_id crossref_primary_10_2147_DDDT_S478388
crossref_primary_10_18632_aging_205149
crossref_primary_10_3390_cells12121585
crossref_primary_10_1083_jcb_202407014
crossref_primary_10_2147_JIR_S403928
crossref_primary_10_3390_ijms25084440
Cites_doi 10.1038/s41571-020-00460-2
10.1155/2021/4061525
10.1016/j.bbadis.2019.02.019
10.1158/1078-0432.CCR-20-3054
10.1186/s12943-022-01500-4
10.1080/10409238.2018.1447542
10.1042/BCJ20160762
10.3390/ijms222111971
10.1016/j.ejphar.2019.01.004
10.3390/ijms21228855
10.1136/jmedgenet-2018-105709
10.1038/s41598-018-32685-8
10.1016/j.cell.2018.03.034
10.1016/j.molonc.2015.06.006
10.1007/s10585-022-10146-x
10.1016/j.bbamcr.2012.04.011
10.3748/wjg.v27.i21.2710
10.1111/bpa.12670
10.1158/1078-0432.CCR-16-2598
10.1016/j.cell.2009.04.042
10.1097/00001622-200201000-00012
10.1016/j.pharmthera.2018.04.004
10.4161/cbt.25329
10.1136/jmedgenet-2015-103334
10.1007/s00281-015-0486-4
10.1016/j.canlet.2019.11.009
10.1038/s41467-020-16142-7
10.1038/nature24451
10.1016/j.bbcan.2021.188609
10.1016/j.cell.2017.01.018
10.1007/978-1-4939-3756-1_3
10.21037/atm.2020.02.136
10.1016/j.ccell.2019.06.009
10.3390/ijms22030986
10.1186/s12964-020-00612-y
10.1038/sj.emboj.7601567
10.1186/s12943-019-1055-6
10.1038/onc.2014.327
10.15252/embj.201489184
10.1016/j.molcel.2021.10.027
10.1016/j.redox.2021.102194
10.1038/s41423-020-0488-6
10.1038/s41388-019-1145-3
10.1158/2326-6066.CIR-18-0910
10.1002/cam4.1675
10.1093/jnci/djy085
ContentType Journal Article
Copyright Copyright © 2022 Li, Wang, Bian, Chen, He, Zhao and Gong.
Copyright © 2022 Li, Wang, Bian, Chen, He, Zhao and Gong. 2022 Li, Wang, Bian, Chen, He, Zhao and Gong
Copyright_xml – notice: Copyright © 2022 Li, Wang, Bian, Chen, He, Zhao and Gong.
– notice: Copyright © 2022 Li, Wang, Bian, Chen, He, Zhao and Gong. 2022 Li, Wang, Bian, Chen, He, Zhao and Gong
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fmolb.2022.886904
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList

CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate Li et al
EISSN 2296-889X
ExternalDocumentID oai_doaj_org_article_0ef44cdcf75d48a2a3e159d7b7a009a3
PMC9273912
10_3389_fmolb_2022_886904
GrantInformation_xml – fundername: ;
  grantid: 202300410019
– fundername: ;
  grantid: 82002592
GroupedDBID 53G
5VS
9T4
AAFWJ
AAYXX
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
GROUPED_DOAJ
HYE
KQ8
M48
M~E
OK1
PGMZT
RPM
7X8
5PM
ID FETCH-LOGICAL-c442t-257f39c8b8325a785afc600557dc60983a175d82c38f85848857a520d16b8f8d3
IEDL.DBID DOA
ISSN 2296-889X
IngestDate Wed Aug 27 01:30:45 EDT 2025
Thu Aug 21 18:15:40 EDT 2025
Fri Jul 11 16:27:18 EDT 2025
Tue Jul 01 02:15:26 EDT 2025
Thu Apr 24 23:02:43 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c442t-257f39c8b8325a785afc600557dc60983a175d82c38f85848857a520d16b8f8d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors have contributed equally to this work
Reviewed by: Chih-Yang Wang, Taipei Medical University, Taiwan
Edited by: Xin Zhang, Jiangmen Central Hospital, China
Urminder Singh, Iowa State University, United States
This article was submitted to Molecular Diagnostics and Therapeutics, a section of the journal Frontiers in Molecular Biosciences
OpenAccessLink https://doaj.org/article/0ef44cdcf75d48a2a3e159d7b7a009a3
PMID 35836933
PQID 2691047820
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_0ef44cdcf75d48a2a3e159d7b7a009a3
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9273912
proquest_miscellaneous_2691047820
crossref_primary_10_3389_fmolb_2022_886904
crossref_citationtrail_10_3389_fmolb_2022_886904
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-06-28
PublicationDateYYYYMMDD 2022-06-28
PublicationDate_xml – month: 06
  year: 2022
  text: 2022-06-28
  day: 28
PublicationDecade 2020
PublicationTitle Frontiers in molecular biosciences
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Zhou (B47) 2021; 1876
Zhang (B44) 2017; 23
Blass (B3) 2021; 18
Li (B14) 2020; 39
Brehm (B39) 2015; 37
Schaefer (B26) 2019; 29
Lei (B13) 2020; 470
Strickler (B32) 2021; 27
Yi (B41) 2019; 56
Zhang (B45) 2020; 17
Wang (B40) 2020; 18
Prasad (B23) 2020; 1866
Braga (B4) 2020; 21
Primeaux (B24) 2022; 39
Toulis (B35) 2016; 1449
Yun (B43) 2015; 9
Conte (B7) 2018; 8
Pan (B20) 2015; 34
Thiagalingam (B34) 2002; 14
Chopra (B5) 2020; 11
Su (B33) 2019; 36
Hou (B9) 2020; 8
Baretti (B2) 2018; 189
Turnbull (B36) 2017; 550
Visani (B38) 2021; 27
Lange (B12) 2022; 82
Perez‐Oliva (B22) 2015; 34
Liu (B16) 2019; 846
McGranahan (B19) 2017; 168
An (B1) 2022; 21
Sowa (B30) 2009; 138
Jingjing (B11) 2018; 7
Hoppe (B8) 2018; 110
Tyagi (B37) 2021; 48
Malta (B18) 2018; 173
Huang (B10) 2019; 7
Seiberlich (B27) 2012; 1823
Smillie (B29) 2018; 53
Zhao (B46) 2021; 11
Li (B15) 2021; 22
Qi (B25) 2015; 52
Stevenson (B31) 2007; 26
Peng (B21) 2019; 18
Collins (B6) 2017; 474
Malhotra (B17) 2013; 14
Yu (B42) 2021; 2021
Sharma (B28) 2021; 22
References_xml – volume: 18
  start-page: 215
  year: 2021
  ident: B3
  article-title: Advances in the Development of Personalized Neoantigen-Based Therapeutic Cancer Vaccines
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-020-00460-2
– volume: 2021
  start-page: 1
  year: 2021
  ident: B42
  article-title: Methylation Modification, Alternative Splicing, and Noncoding RNA Play a Role in Cancer Metastasis through Epigenetic Regulation
  publication-title: BioMed Res. Int.
  doi: 10.1155/2021/4061525
– volume: 1866
  start-page: 165424
  year: 2020
  ident: B23
  article-title: Cancer Cells Stemness: A Doorstep to Targeted Therapy
  publication-title: Biochim. Biophys. Acta (BBA) - Mol. Basis Dis.
  doi: 10.1016/j.bbadis.2019.02.019
– volume: 27
  start-page: 1236
  year: 2021
  ident: B32
  article-title: Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-20-3054
– volume: 21
  start-page: 14
  year: 2022
  ident: B1
  article-title: The Role of m6A RNA Methylation in Cancer Metabolism
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-022-01500-4
– volume: 53
  start-page: 231
  year: 2018
  ident: B29
  article-title: Complexities of Post-transcriptional Regulation and the Modeling of ceRNA Crosstalk
  publication-title: Crit. Rev. Biochem. Mol. Biol.
  doi: 10.1080/10409238.2018.1447542
– volume: 474
  start-page: 1127
  year: 2017
  ident: B6
  article-title: Chemical Approaches to Targeted Protein Degradation through Modulation of the Ubiquitin-Proteasome Pathway
  publication-title: Biochem. J.
  doi: 10.1042/BCJ20160762
– volume: 22
  start-page: 11971
  year: 2021
  ident: B28
  article-title: Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms222111971
– volume: 846
  start-page: 1
  year: 2019
  ident: B16
  article-title: Auranofin Lethality to Prostate Cancer Includes Inhibition of Proteasomal Deubiquitinases and Disrupted Androgen Receptor Signaling
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2019.01.004
– volume: 21
  start-page: 8855
  year: 2020
  ident: B4
  article-title: LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms21228855
– volume: 56
  start-page: 325
  year: 2019
  ident: B41
  article-title: Biallelic Mutations in USP45, Encoding a Deubiquitinating Enzyme, Are Associated with Leber Congenital Amaurosis
  publication-title: J. Med. Genet.
  doi: 10.1136/jmedgenet-2018-105709
– volume: 8
  start-page: 14375
  year: 2018
  ident: B7
  article-title: USP45 and Spindly Are Part of the Same Complex Implicated in Cell Migration
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-018-32685-8
– volume: 173
  start-page: 338
  year: 2018
  ident: B18
  article-title: Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
  publication-title: Cell
  doi: 10.1016/j.cell.2018.03.034
– volume: 9
  start-page: 1834
  year: 2015
  ident: B43
  article-title: Ubiquitin Specific Protease 4 Positively Regulates the WNT/beta-catenin Signaling in Colorectal Cancer
  publication-title: Mol. Oncol.
  doi: 10.1016/j.molonc.2015.06.006
– volume: 39
  start-page: 391
  year: 2022
  ident: B24
  article-title: Role of CD44 Isoforms in Epithelial-Mesenchymal Plasticity and Metastasis
  publication-title: Clin. Exp. Metastasis
  doi: 10.1007/s10585-022-10146-x
– volume: 1823
  start-page: 2057
  year: 2012
  ident: B27
  article-title: The Small Molecule Inhibitor PR-619 of Deubiquitinating Enzymes Affects the Microtubule Network and Causes Protein Aggregate Formation in Neural Cells: Implications for Neurodegenerative Diseases
  publication-title: Biochim. Biophys. Acta (BBA) - Mol. Cell Res.
  doi: 10.1016/j.bbamcr.2012.04.011
– volume: 27
  start-page: 2710
  year: 2021
  ident: B38
  article-title: Molecular Alterations in Pancreatic Tumors
  publication-title: World J Gastroenterol.
  doi: 10.3748/wjg.v27.i21.2710
– volume: 29
  start-page: 336
  year: 2019
  ident: B26
  article-title: Regulation of Glioma Cell Invasion by 3q26 Gene Products PIK3CA, SOX2 and OPA1
  publication-title: Brain Pathol.
  doi: 10.1111/bpa.12670
– volume: 23
  start-page: 6279
  year: 2017
  ident: B44
  article-title: Tumor Purity as an Underlying Key Factor in Glioma
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-2598
– volume: 138
  start-page: 389
  year: 2009
  ident: B30
  article-title: Defining the Human Deubiquitinating Enzyme Interaction Landscape
  publication-title: Cell
  doi: 10.1016/j.cell.2009.04.042
– volume: 14
  start-page: 65
  year: 2002
  ident: B34
  article-title: Loss of Heterozygosity as a Predictor to Map Tumor Suppressor Genes in Cancer: Molecular Basis of its Occurrence
  publication-title: Curr. Opin. Oncol.
  doi: 10.1097/00001622-200201000-00012
– volume: 189
  start-page: 45
  year: 2018
  ident: B2
  article-title: DNA Mismatch Repair in Cancer
  publication-title: Pharmacol. Ther.
  doi: 10.1016/j.pharmthera.2018.04.004
– volume: 14
  start-page: 840
  year: 2013
  ident: B17
  article-title: Chromosomal Structural Variations during Progression of a Prostate Epithelial Cell Line to a Malignant Metastatic State Inactivate the NF2, NIPSNAP1, UGT2B17, and LPIN2 Genes
  publication-title: Cancer Biol. Ther.
  doi: 10.4161/cbt.25329
– volume: 52
  start-page: 710
  year: 2015
  ident: B25
  article-title: ceRNA in Cancer: Possible Functions and Clinical Implications
  publication-title: J. Med. Genet.
  doi: 10.1136/jmedgenet-2015-103334
– volume: 37
  start-page: 323
  year: 2015
  ident: B39
  article-title: Dysfunction in Protein Clearance by the Proteasome: Impact on Autoinflammatory Diseases
  publication-title: Seminars in Immunopathology
  doi: 10.1007/s00281-015-0486-4
– volume: 470
  start-page: 126
  year: 2020
  ident: B13
  article-title: Immune Cells within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2019.11.009
– volume: 11
  start-page: 2662
  year: 2020
  ident: B5
  article-title: Homologous Recombination DNA Repair Deficiency and PARP Inhibition Activity in Primary Triple Negative Breast Cancer
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-16142-7
– volume: 550
  start-page: 481
  year: 2017
  ident: B36
  article-title: Molecular Basis of USP7 Inhibition by Selective Small-Molecule Inhibitors
  publication-title: Nature
  doi: 10.1038/nature24451
– volume: 1876
  start-page: 188609
  year: 2021
  ident: B47
  article-title: The RNA m6A Writer METTL14 in Cancers: Roles, Structures, and Applications
  publication-title: Biochim. Biophys. Acta (BBA) - Rev. Cancer
  doi: 10.1016/j.bbcan.2021.188609
– volume: 168
  start-page: 613
  year: 2017
  ident: B19
  article-title: Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
  publication-title: Cell
  doi: 10.1016/j.cell.2017.01.018
– volume: 1449
  start-page: 85
  year: 2016
  ident: B35
  article-title: Combining Zebrafish and Mouse Models to Test the Function of Deubiquitinating Enzyme (Dubs) Genes in Development: Role of USP45 in the Retina
  publication-title: Methods Mol. Biol.
  doi: 10.1007/978-1-4939-3756-1_3
– volume: 8
  start-page: 339
  year: 2020
  ident: B9
  article-title: Prognostic Significance of Mutant-Allele Tumor Heterogeneity in Uterine Corpus Endometrial Carcinoma
  publication-title: Ann. Transl. Med.
  doi: 10.21037/atm.2020.02.136
– volume: 36
  start-page: 139
  year: 2019
  ident: B33
  article-title: The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.06.009
– volume: 22
  start-page: 986
  year: 2021
  ident: B15
  article-title: Molecular Mechanisms of DUBs Regulation in Signaling and Disease
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms22030986
– volume: 18
  start-page: 112
  year: 2020
  ident: B40
  article-title: The Deubiquitinase USP22 Regulates PD-L1 Degradation in Human Cancer Cells
  publication-title: Cell Commun. Signal
  doi: 10.1186/s12964-020-00612-y
– volume: 11
  start-page: 6119
  year: 2021
  ident: B46
  article-title: Automated Assessment of DNA Ploidy, Chromatin Organization, and Stroma Fraction to Predict Prognosis and Adjuvant Therapy Response in Patients with Stage II Colorectal Carcinoma
  publication-title: Am. J. Cancer Res.
– volume: 26
  start-page: 976
  year: 2007
  ident: B31
  article-title: The Deubiquitinating Enzyme USP2a Regulates the P53 Pathway by Targeting Mdm2
  publication-title: EMBO J.
  doi: 10.1038/sj.emboj.7601567
– volume: 18
  start-page: 128
  year: 2019
  ident: B21
  article-title: Neoantigen Vaccine: an Emerging Tumor Immunotherapy
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-019-1055-6
– volume: 34
  start-page: 3957
  year: 2015
  ident: B20
  article-title: USP37 Directly Deubiquitinates and Stabilizes C-Myc in Lung Cancer
  publication-title: Oncogene
  doi: 10.1038/onc.2014.327
– volume: 34
  start-page: 326
  year: 2015
  ident: B22
  article-title: USP45 Deubiquitylase Controls ERCC1-XPF Endonuclease-Mediated DNA Damage Responses
  publication-title: EMBO J.
  doi: 10.15252/embj.201489184
– volume: 82
  start-page: 15
  year: 2022
  ident: B12
  article-title: Deubiquitinases: From Mechanisms to Their Inhibition by Small Molecules
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2021.10.027
– volume: 48
  start-page: 102194
  year: 2021
  ident: B37
  article-title: Redox Regulation of DUBs and its Therapeutic Implications in Cancer
  publication-title: Redox Biol.
  doi: 10.1016/j.redox.2021.102194
– volume: 17
  start-page: 807
  year: 2020
  ident: B45
  article-title: The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-Infiltrating Immune Cells and Their Therapeutic Implications
  publication-title: Cell Mol. Immunol.
  doi: 10.1038/s41423-020-0488-6
– volume: 39
  start-page: 2258
  year: 2020
  ident: B14
  article-title: He Wnt/Beta-Catenin/VASP Positive Feedback Loop Drives Cell Proliferation and Migration in Breast Cancer
  publication-title: Oncogene
  doi: 10.1038/s41388-019-1145-3
– volume: 7
  start-page: 1580
  year: 2019
  ident: B10
  article-title: USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-18-0910
– volume: 7
  start-page: 4004
  year: 2018
  ident: B11
  article-title: Deubiquitination and Stabilization of Programmed Cell Death Ligand 1 by Ubiquitin-Specific Peptidase 9, X-Linked in Oral Squamous Cell Carcinoma
  publication-title: Cancer Med.
  doi: 10.1002/cam4.1675
– volume: 110
  start-page: 704
  year: 2018
  ident: B8
  article-title: Biomarkers for Homologous Recombination Deficiency in Cancer
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djy085
SSID ssj0001503764
Score 2.2480476
Snippet Background: Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of...
Background: Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 886904
SubjectTerms deubiquitinating enzyme
Molecular Biosciences
pan-cancer analysis
TCGA (The Cancer Genome Atlas Program)
tumor immunotherapy
USP45
SummonAdditionalLinks – databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEB3SLYVeSpO0dPuFAj0VXLSSbMuHUtrQEAL7QdOF3IQkS01gsVvvbmj-fWdsb6gh5JSTwZawNaOH3kjjNwAfrPAFzyircZJniXKRJ4VVPNHeCy9pp8HS1sB0lp0u1dlFerEHu_JWvQHXd4Z2VE9q2aw-_f1z8wUB_5kiTlxv0QP1ymGoJwS6HaM99Qge48KUE06nPdvvfhrmCCfVnW3e3XOwOrUi_gPmOcyb_G8hOnkOz3oGyb52Lt-HvVAdwJOupuTNIcwJ4U247BLT2U50hP0I18gJ12x5vlAps2tm2ay-Diu22G5a8W82r3yN0ymwq4otbJUc04RoXsDy5PvP49Okr5qQeKXEJkEMRll47RCrqc11aqPPWqmtEq-FlhYZQ6nJE1Ej_dA6zW0qeDnJHN4p5UsYVXUVXgHzEcMdl09ixqWSZbDaFTxGqbBXFqIbA99Zy_heUpwqW6wMhhZkYNMa2JCBTWfgMXy87fK709O4r_E3csFtQ5LCbm_UzS_TI8vwEJXypY84KqWtsDIgRStzl1vkj1aO4WjnQIPQofMQW4V6uzYiK1pxIsHHkA88O3jj8El1ddmKcBfI-4qJeP0Qn_gGntKoKQNN6Lcw2jTb8A65zsa9b2fwP2Ti_dU
  priority: 102
  providerName: Scholars Portal
Title Comprehensive Analysis Reveals USP45 as a Novel Putative Oncogene in Pan-Cancer
URI https://www.proquest.com/docview/2691047820
https://pubmed.ncbi.nlm.nih.gov/PMC9273912
https://doaj.org/article/0ef44cdcf75d48a2a3e159d7b7a009a3
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1JS8QwFA4iCF7EFceNCJ6EYiZN2-SogyLCLKgDcwtJmqAwtDIb-O99SWaG6UUvXlpIE5q-hXwvef0eQjeKGkFyn9XYLvKEaUcSoRhJuDHUpH6nQfmtgW4vfx6yl1E22ij15XPCIj1wFNwdsY4xUxpXZCXjiqrUwgpcFrpQAA9U4PmENW8jmIr_BxPwHBaPMSEKE6CmeqwhHqQUbANCQtZYiAJffwNkNlMkN9acp320twSL-D5O8gBt2eoQ7cTykd9HqO-deWI_Yg46XvGL4Fe7APg3xcO3AcuwmmKFe_XCjvFgPgs837hfmRosx-LPCg9UlXS87ifHaPj0-N55TpYFEhLDGJ0l4G4uFYZrcMtMFTxTzuSBVauEu-CpAnBQci90xwFpcJ4VKqOkbOcaWsr0BG1XdWVPETYOIhtdtF1OUpaWVnEtiHMpg1G5dbqFyEpa0izZw30Ri7GEKMILWAYBSy9gGQXcQrfrIV-ROuO3zg9eBeuOnvU6NIAtyKUtyL9soYWuVwqU4CX-6ENVtp5PJc1F4CGipIWKhmYbb2w-qT4_At-2AIgn2vTsP6Z4jnb9V_tkM8ov0PZsMreXAGtm-ipYMFy7jP8AMcr2tQ
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comprehensive+Analysis+Reveals+USP45+as+a+Novel+Putative+Oncogene+in+Pan-Cancer&rft.jtitle=Frontiers+in+molecular+biosciences&rft.au=Kai+Li&rft.au=Kai+Li&rft.au=Qian+Wang&rft.au=Qian+Wang&rft.date=2022-06-28&rft.pub=Frontiers+Media+S.A&rft.eissn=2296-889X&rft.volume=9&rft_id=info:doi/10.3389%2Ffmolb.2022.886904&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_0ef44cdcf75d48a2a3e159d7b7a009a3
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2296-889X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2296-889X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2296-889X&client=summon